Capricor Therapeutics Inc Asset Resilience Ratio
Capricor Therapeutics Inc asset resilience ratio. Capricor Therapeutics Inc (CAPR) has an Asset Resilience Ratio of 53.08% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See CAPR defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Capricor Therapeutics Inc (2011–2025)
Asset resilience ratio of Capricor Therapeutics Inc from 2011 to 2025. This chart shows how Capricor Therapeutics Inc's Asset Resilience Ratio has changed over time. Read Capricor Therapeutics Inc balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Capricor Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see CAPR total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $173.19 Million | 53.08% |
| Total Liquid Assets | $173.19 Million | 53.08% |
Asset Resilience Insights
- Very High Liquidity: Capricor Therapeutics Inc maintains exceptional liquid asset reserves at 53.08% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Capricor Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Capricor Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940 |
Biotechnology | 15.21% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821 |
Biotechnology | 5.07% |
|
Immunovant Inc
NASDAQ:IMVT |
Biotechnology | 98.50% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Amicus Therapeutics Inc
NASDAQ:FOLD |
Biotechnology | 8.37% |
Capricor Therapeutics Inc Asset Resilience Ratio by Year (2011–2025)
Capricor Therapeutics Inc asset resilience ratio by year from 2011 to 2025. The table below shows the annual Asset Resilience Ratio data for Capricor Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 8.51% | $30.28 Million | $355.95 Million | -73.75pp |
| 2024-12-31 | 82.25% | $140.23 Million | $170.48 Million | +40.04pp |
| 2023-12-31 | 42.21% | $24.79 Million | $58.73 Million | -21.30pp |
| 2022-12-31 | 63.52% | $31.82 Million | $50.09 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $41.33 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $34.62 Million | -- |
| 2019-12-31 | 53.86% | $5.99 Million | $11.11 Million | +21.45pp |
| 2018-12-31 | 32.41% | $3.00 Million | $9.25 Million | -16.65pp |
| 2017-12-31 | 49.07% | $7.98 Million | $16.27 Million | -20.23pp |
| 2016-12-31 | 69.29% | $12.99 Million | $18.75 Million | +19.52pp |
| 2015-12-31 | 49.78% | $8.00 Million | $16.07 Million | +27.94pp |
| 2014-12-31 | 21.84% | $2.98 Million | $13.63 Million | +15.94pp |
| 2013-12-31 | 5.90% | $326.49K | $5.54 Million | -71.41pp |
| 2012-12-31 | 77.31% | $4.19 Million | $5.42 Million | -- |
| 2011-12-31 | 0.00% | $0.00 | $1.37 Million | -- |
About Capricor Therapeutics Inc
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treat… Read more